Janumet XR and Cancer

If you or a family member have taken Janumet XR and cancer developed, investigate your potential claim against the drugmaker by talking with a lawyer experienced in successfully handling cases against large pharmaceutical manufacturers. The mass torts law firm Watts Guerra LLP is currently handling the nation’s largest incretins pancreatic cancer injury and wrongful death docket. Contact the firm now to find out how they can help you and your family.

Janumet XR – A New Treatment for Type 2 Diabetes

In February 2012, drugmaker Merck announced approval by the U.S. Food and Drug Administration (FDA) of Janumet XR, a new treatment for type 2 diabetes. Like Janumet, the XR is a combination medication containing the active drug sitagliptin, a DPP-4 inhibitor, and metformin, a commonly prescribed glucose lowering agent. The difference is that the metformin in Janumet XR is an extended-release. Type 2 diabetics take the table once daily.

As with other brands of sitagliptin ( Januvia, Janumet, and Juvisync), Janumet XR is prescribed to help type 2 diabetics control their blood sugar levels. However, like the other brands, Janumet XR may increase the risk of pancreatic cancer.

Janumet XR & Pancreatic Cancer

Deep within the company announcement about the FDA approval of Janumet XR, Merck warned there have been post-marketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking sitagliptin with or without metformin. In 2009 the FDA revised prescription information for sitagliptin drugs Januvia and Janumet to include information about reported cases of acute pancreatitis. According to the FDA, 88 cases of acute pancreatitis were reported from 2006 when sitagliptin first hit the U.S. market through 2009. Pancreatitis risks can also increase the risk of pancreatic cancer.

Before Merck’s release of Janumet XR, multiple studies had shown an association between sitagliptin and other incretin-based drugs and pancreatic cancer. The FDA is now investigating that association after new findings by an academic research group showed an increased risk in pre-cancerous cellular changes in patients taking these dangerous diabetes drugs.

Pancreatic Cancer Lawsuit Against Janumet XR Maker

Lawyers of Watts Guerra LLP believe Merck failed to adequately warn healthcare practitioners and consumers about the risk of serious and potentially fatal side effects of Janumet XR and other sitagliptin brands. If you or a member of your family took Janumet XR and cancer developed, we encourage you to contact our firm for a free case review. A successful pancreatic cancer lawsuit against a pharmaceutical company like Merck needs highly experienced legal representation. The trial lawyers of Watts Guerra LLPhave that experience.

Disclaimer: The images on this page of the Januvia packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Merck & Co., Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.
Contact us using our online form, or call us toll-free at 1(800)796-9605.